

9/18/05

04-20-2005

Form PTO-1595 (Rev. 09/04)
OMB No. 0651-0027 (exp. 6/30/2005)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office



102985167

IT

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)/Execution Date(s): Novartis AG Execution Date(s) <u>11/05/2004</u> Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies) Name: <u>Syngenta Participations AG</u> Internal Address: _____ Street Address: <u>Schwarzwaldallee 215</u> City: <u>Basel</u> State: _____ Country: <u>Switzerland</u> Zip: <u>4058</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other _____	

4. Application or patent number(s): A. Patent Application No.(s) Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> This document is being filed together with a new application. B. Patent No.(s) <u>6,057,492</u> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
--	--

RECEIVED
APR 18 PM 4:13
OPR/FINANCE

5. Name and address to whom correspondence concerning document should be mailed: Name: <u>Larry W. Stults</u> Internal Address: <u>Syngenta Biotechnology, Inc.</u> Street Address: <u>3054 Cornwallis Road</u> City: <u>Research Triangle Park</u> State: <u>NC</u> Zip: <u>27709</u> Phone Number: <u>919-765-5117</u> Fax Number: <u>919-541-8689</u> Email Address: <u>edouard.lebel@syngenta.com</u>	6. Total number of applications and patents involved: <u>1</u> 7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00 <input checked="" type="checkbox"/> Authorized to be charged by credit card <input type="checkbox"/> Authorized to be charged to deposit account <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title) 8. Payment Information a. Credit Card Last 4 Numbers <u>8991</u> Expiration Date <u>4/06</u> b. Deposit Account Number _____ Authorized User Name _____
--	--

9. Signature: <u>Edouard G. Lebel</u> Signature Edouard G. Lebel, Ph.D., Reg. No. 43,742 Name of Person Signing	<u>4/14/2005</u> Date Total number of pages including cover sheet, attachments, and documents: <u>3</u>
---	---

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

04/19/2005 ECOOPER 00000176 6057492
01 FC:3021 40.00 OP

PATENT
REEL: 016460 FRAME: 0428

ASSIGNMENT

NOVARTIS AG, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056,


for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, hereby assigns to **Syngenta Participations AG**, a Swiss corporation, having a place of business at Schwarzwaldalle 215, Basel, Switzerland 4058, its successors, assigns and legal representatives, all right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the inventions described in the applications for United States Letters Patent


Atty. Docket No.	Application Ser. No.	Filing date	Patent No.	Issue date
135-1087	08/272,439	08/JUL/1994	5,530,181	25/JUN/1996
137-1061	08/32,235	17/MAR/1993		
137-1035	625,326	10/DEC/1990	5,254,802	19/OCT/1993
137-1063	08/437,828	09/MAY/1995	5,585,540	17/DEC/1996
137-1064	08/387,759	31/AUG/1993	5,585,536	17/DEC/1996
137-1064	08/449,624	24/MAY/1995	5,522,907	04/JUN/1996
137-1068	08/406,822	20/MAR/1995	5,587,312	24/DEC/1996
137-1099	08/913,374	22/MAR/1996	6,057,492	02/MAY/2000
135-2003	08/572,832	14/DEC/1995	PP 9,803	11/FEB/1997
135-2004	08/572,561	14/DEC/1995	PP 9,802	11/FEB/1997
137-1061	08/764,100	06/DEC/1996	5,773,700	30/JUN/1998
137-1093	09/572,212	17/MAY/2000	6,385,902	14/MAY/2002
137-1093	08/667,167	20/JUN/1996	6,313,377	06/NOV/2001
135-2006	08/732,008	16/OCT/1996	5,817,914	06/OCT/1998
135-1090	08/716,836	22/AUG/1996	5,731,503	24/MAR/1998
135-1091	08/690,252	24/JUL/1996	5,728,924	17/MAR/1998
135-2000	08/727,876	09/OCT/1996	5,792,905	11/AUG/1998


including (1) said applications for United States Letters Patent and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be


issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said assignee and its successors and assigns to the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by assignor if this sale, assignment and transfer had not been made;

And assignor hereby agrees to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this 5th day of November , 2004 by 
Werner Bastian (on behalf of Novartis AG)

Signed this 5th day of November , 2004 by 
Ingo Hoelscher (on behalf of Novartis AG)

Signed this 5th day of November , 2004 by 
Jocelyne Ceroni (on behalf of Syngenta Participations AG)

Signed this 5th day of November, 2004 by 
Cornelia Ebinger-Zöld (on behalf of Syngenta Participations AG)